Company

Caladrius Biosciences, Inc.

Headquarters: Basking Ridge, NJ, United States

Founded: 2006 (2006)

Employees: 27

CEO: Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.

NASDAQ: CLBS -0.36%

Market Cap

$10.9 Million

USD as of Jan. 1, 2024

Market Cap History

Caladrius Biosciences, Inc. market capitalization over time

Evolution of Caladrius Biosciences, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Caladrius Biosciences, Inc.

Detailed Description

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Top 1-year algo backtest: +269.94%

$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Caladrius Biosciences, Inc. has the following listings and related stock indices.


Stock: NASDAQ: CLBS wb_incandescent

Stock: FSX: 8NE2 wb_incandescent

Key People

David J. Mazzo (CEO)

Details

Headquarters:

110 Allen Road

2nd Floor

Basking Ridge, NJ 07920

United States

Phone: 908 842 0100